Able Tx is a clinical-stage ophthalmic biopharmaceutical company developing non-invasive, self-applied therapies for vision-threatening retinal and corneal diseases. Its proprietary Smatrix platform is a miniature, degradable, drug-eluting matrix made from FDA-approved excipients, enabling sustained delivery with injection-like efficacy via simple topical use.

The lead retinal program, AMX300, targets DME, RVO, and uveitis and is in Phase 2 with positive early efficacy. The lead corneal program, AMX500, targets PED, NK, and DED and is expected to enter patients in early 2026. To date, over 80 patients have been treated across programs, demonstrating strong safety, efficacy, and usability.

Able Tx aims to replace invasive intravitreal injections with first-line, at-home therapies for diseases affecting ~20M patients in the U.S., supported by a robust global IP portfolio.